IceCure Medical VP reports initial share holdings

IceCure Medical Ltd. executive Good Shad, VP Sales for North America, filed an initial statement of ownership showing 156,455 ordinary shares, composed of 6,578 shares and multiple RSU grants that remained unvested as of March 18, 2026.

Accepted by SEC EDGAR 03/25/2026 - 05:13 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

IceCure Medical Ltd. executive Good Shad, VP Sales for North America, filed an initial statement of ownership showing 156,455 ordinary shares, composed of 6,578 shares and multiple RSU grants that remained unvested as of March 18, 2026. He also holds options to buy 50,000 ordinary shares at $1.22 per share expiring on August 14, 2033, and options on 72,756 ordinary shares at $0.92 per share expiring on July 2, 2034, with portions of each option grant already vested by that date.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Good Shad

Role VP, Sales for North America

Type	Security	Shares	Price	Value
Holding	Share option (right to buy)	--	--	--
Holding	Share option (right to buy)	--	--	--
Holding	Ordinary shares	--	--	--

Holdings: Share option (right to buy) — 122,756 contracts (Direct); Ordinary shares — 156,455 shares (Direct)

Footnotes (3)

1. F1. Represents (i) 6,578 ordinary shares, (ii) 60,630 restricted stock units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of remain unvested as of March 18, 2026, (iii) 52,719 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iv) 36,528 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.
2. F2. The options were granted on August 14, 2023, 25% of which vested on August 14, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 31,250 options are vested.
3. F3. Share option was granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 27,283 options are vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does IceCure Medical (ICCM) disclose about Good Shad’s share ownership?

IceCure Medical discloses that VP Sales for North America, Good Shad, reports beneficial ownership of 156,455 ordinary shares. This total includes 6,578 shares plus several RSU grants that remained unvested as of March 18, 2026.

What stock options does Good Shad hold in IceCure Medical (ICCM)?

Good Shad holds options to buy 50,000 ordinary shares at $1.22 per share expiring on August 14, 2033. He also holds options on 72,756 ordinary shares at $0.92 per share expiring on July 2, 2034.

How many IceCure Medical (ICCM) RSUs are reported for Good Shad?

The filing notes RSU grants totaling 149,877 units: 60,630 RSUs from July 2, 2024, 52,719 RSUs from November 5, 2025, and 36,528 RSUs from March 16, 2026, all unvested as of March 18, 2026.

What portion of Good Shad’s IceCure Medical (ICCM) options are vested?

As of March 18, 2026, 31,250 options from the August 14, 2023 grant are vested. From the July 2, 2024 grant, 27,283 options are vested, with the remaining options vesting in specified quarterly installments.

Is there any buy or sell transaction in this IceCure Medical (ICCM) Form 3?

No buy or sell transactions are reported; the entries are classified as holdings. The Form 3 simply establishes Good Shad’s existing ordinary share, RSU, and option positions as of March 18, 2026, without recording new trades.

What role does Good Shad hold at IceCure Medical (ICCM)?

Good Shad is identified as an officer of IceCure Medical, serving as VP, Sales for North America. His Form 3 filing details his equity-based compensation and ownership in the company, including ordinary shares, RSUs, and stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Good Shad

(Last) (First) (Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA 3079504

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP, Sales for North America

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	156,455(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share option (right to buy)	(2)	08/14/2033	Ordinary shares	50,000	$1.22	D
Share option (right to buy)	(3)	07/02/2034	Ordinary shares	72,756	$0.92	D

Explanation of Responses:

1. Represents (i) 6,578 ordinary shares, (ii) 60,630 restricted stock units ("RSUs") granted on July 2, 2024, 25% of which vest on July 29, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of remain unvested as of March 18, 2026, (iii) 52,719 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026, and (iv) 36,528 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027 and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, all of which remain unvested as of March 18, 2026.

2. The options were granted on August 14, 2023, 25% of which vested on August 14, 2024, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 31,250 options are vested.

3. Share option was granted on July 2, 2024, 25% of which vested on July 2, 2025, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. As of March 18, 2026, 27,283 options are vested.

	/s/ Shad Good	03/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)